BirchBioMed Inc., a pioneering clinical-stage Canadian biopharmaceutical company, today (28th February 2025) joins in solidarity with the global community to recognize Rare Disease Day #RareDiseaseDay and underscore the vital importance of raising awareness about the more than 400 million children and adults who live with rare diseases worldwide. Rare Disease Day provides the international community with an opportunity to a focus and commit to addressing the high unmet medical needs of those suffering from one of more than 7,000 rare diseases. We join in renewing our commitment to those individuals and their families and playing an integral role in the efforts of caregivers, healthcare professionals, researchers, clinicians, policymakers, industry representatives, and the public in seeking to find and develop proper, accurate and early diagnosis, as well as innovative, safe and effective treatment options for this vulnerable population in urgent need. At BirchBioMed, our team of world-class scientists, researchers, and business professionals are dedicated to the development of groundbreaking therapies for diseases with high unmet medical needs, including organ fibrosis, scarring, skin disorders, and specific autoimmune conditions including Type-1 Diabetes (T1D).
